310 results about "Carrier protein" patented technology

The technology described herein relates to novel CRISPR / Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the novel systems and components. The new system can be used in CRIS PRi applications and can be fused with any number of effector domain patterns, such as nuclease, base editor, leader editor, and the like, to conduct a variety of DNA modifications.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The invention discloses a test strip for detecting etoxazole and application of the test strip. The test strip comprises a sample absorption pad (1), a conjugate release pad (2), a reaction film (3), a water absorption pad (4) and a bottom plate (7), the reaction film is provided with a detection line (5) coated with an etoxazole hapten-carrier protein conjugate and a quality control line (6) coated with a goat anti-mouse antibody, and the conjugate release pad (2) is sprayed with an etoxazole monoclonal antibody-colloidal gold marker. The invention also provides a method for detecting residual etoxazole in vegetables and fruits by using the etoxazole test strip. The test strip provided by the invention has the characteristics of simplicity in operation, high sensitivity, high detection speed, low cost and the like, and is suitable for screening and on-site monitoring of a large number of samples.

The invention discloses a preparation method of collagen nano polymer particles, which comprises the following steps: carrying out surface hydrolysis on organized collagen to prepare a microsphere base material; the preparation method comprises the following steps: uniformly mixing a microsphere base material, a target load, a nonionic surfactant and polyol ester in proportion to prepare a microsphere modified base material; and uniformly mixing the microsphere modified base material, an ether compound and a chemical auxiliary agent according to a ratio to prepare collagen microspheres, namely the collagen nano polymer particles. The preparation method comprises the following steps: firstly, reducing the volume of collagen through enzyme hydrolysis, reducing biological stimulation possibly caused by drug loading, and strengthening the drug loading property of the collagen nano polymer; and secondly, a polymer crystal region appears in the carrier protein in an aqueous solution by utilizing subsequent surface modification, so that the drug carrier can control the release progress of the loaded drug, and the drug carrier can permeate into deep tissues through the surface layer of the skin.

The invention provides a safrole hapten and application of the safrole hapten in detection of safrole through immunoassay. The structure of the safrole hapten is shown in the specification. The two safrole haptens provided by the invention have spacer arms with proper lengths, and after the safrole haptens are coupled with carrier protein, the haptens can be fully exposed, and recognition of the spacer arms can be avoided as much as possible. The safrole hapten is used for preparing an artificial antigen and an antibody, and the obtained safrole monoclonal antibody is high in titer, strong in specificity and high in affinity. An immunoassay method constructed on the basis of the safrole artificial antigen and antibody has high specificity and sensitivity, the lowest detection limit LOD is 0.09 ng / mL, the half inhibitory concentration IC50 is 2.05 ng / mL, the quantitative detection range is 0.28-14.89 ng / mL, no cross reaction exists on safrole analogues, and rapid qualitative and quantitative detection can be conducted on safrole in a sample.

The present invention relates to the field of biomedicine, and particularly to an assembled protein nanocarrier CABRi for targeted delivery of small interfering nucleic acids, its preparation method and application. The assembled protein nanocarrier CABRi (CABRi series of siRNA protein delivery carriers) designed by the present invention can efficiently load siRNA without sequence selectivity, and can be mixed with one or more siRNAs in a certain ratio to form a carrier / small nucleic acid complex CABRi-siRNA, which self-assembles into a nanoparticle with a size of 10-100 nm. The present invention constructs a brand-new siRNA delivery carrier, breaking through three key technical bottlenecks in siRNA drug delivery, namely, extremely low in vivo delivery efficiency of siRNA, endosomal escape and extrahepatic delivery problems, and finally achieving the purposes of efficient delivery, endosomal escape, targeting extrahepatic organs or tumors, high safety and easy industrialization of siRNA drugs.

The present disclosure provides lysosomal targeting bifunctional molecules that target disease causing anti-TSHR autoantibodies for degradation. The lysosomal targeting bifunctional molecules include a ligand moiety that specifically binds to an asialoglycoprotein receptor (ASGPR), and which is linked via a carrier protein to a thyroid stimulating hormone receptor (TSHR) polypeptide that specifically binds target anti-TSHR autoantibodies.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

The invention discloses a phthalimidic acid hapten, an artificial antigen, an antibody, and a preparation method and application of the phthalimidic acid hapten and the artificial antigen. The structure of the phthalimide acid hapten is shown as a formula (I), and the phthalimide acid hapten is obtained by introducing a carboxyl active group with a spacer arm with a certain length to carboxyl of phthalimide acid, so that the phthalimide acid hapten can be coupled with carrier protein to obtain an artificial antigen for immunization; the phthalimide hapten retains all characteristic groups of the phthalimide, the original structural characteristics of the phthalimide are changed to the minimum extent, and a foundation is laid for generating an antibody with higher specificity and higher sensitivity for subsequently stimulating animal immune response. An artificial antigen and a phthalimide acid monoclonal antibody are prepared through the hapten, indirect competitive ELISA based on the monoclonal antibody has the lowest detection limit of phthalimide acid of 2.44 ng / mL, IC50 of 17.29 ng / mL and the linear range of 5.02-59.51 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention discloses a method for improving the water-retaining property of meat paste, which specifically comprises the following steps: firstly, sufficiently tumbling and chopping fresh meat paste to be treated at low temperature, and adjusting the pH value of the meat paste to be neutral; then, protein-phospholipid composite emulsion is added into the meat paste, the protein-phospholipid composite emulsion is prepared by mixing phospholipid extracted from livestock and poultry head tissues, a carrier protein solution and algal polysaccharides, then mixing the mixture with edible oil, performing ultrasonic treatment, emulsifying and homogenizing, and finally, a small amount of the protein-phospholipid composite emulsion is added into the pretreated meat paste for many times, and homogenizing at high pressure, adding transglutaminase, and packaging in vacuum. The method is simple, the steps are easy to operate, the pH value of the meat paste can be reduced, the loss rate of juice in the meat paste can be reduced, the water-retaining property of the meat paste can be improved, and meanwhile, the structural stability of the meat paste can be enhanced by improving the combination of fat and water.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

The present invention relates to a recombinant organism or microorganism having a decreased pool of crotonic acid compared to the organism or microorganism from which it is derived due to at least one of: (i) an increased conversion of crotonyl-CoA into butyryl-CoA; and / or an increased conversion of butyryl-CoA into butyric acid; (ii) an increased conversion of crotonyl-CoA into 3-hydroxybutyryl-CoA; and / or an increased conversion of 3-hydroxybutyryl-CoA into 3-hydroxybutyric acid; (iii) an increased conversion of crotonic acid into crotonyl-CoA; (iv) an increased conversion of crotonyl-[acyl-carrier protein] into butyryl [acyl-carrier-protein]; (v) a decreased conversion of crotonyl-CoA into crotonic acid; and / or (vi) a decreased conversion of crotonyl-[acyl-carrier protein] into crotonic acid. Moreover, the present invention relates to the use of such a recombinant organism or microorganism for the production of alkenes with the enzyme ferulic acid decarboxylase. Further, the present invention relates to a method for the production of isobutene or butadiene by culturing such a recombinant organism or microorganism in a suitable culture medium under suitable conditions.

The invention discloses a carrier protein with an adjuvant function and application thereof. The carrier protein with the adjuvant function has a sequence as shown in SEQ ID NO. 1. According to the carrier protein with the adjuvant function, a part of sequence is intercepted from the flagellin FliC of Burkholderia cepacia, so that the adjuvant activity of the flagellin is reserved, and the immunogenicity and antigenicity of the flagellin are reduced; when being applied to a fusion protein or a small-molecule drug, the fusion protein or the small-molecule drug can enhance the immunogenicity, so that the fusion protein or the small-molecule drug has important significance on subunit vaccines, polypeptide vaccines or small-molecule drug carriers.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The present invention discloses a method for increasing the yield of maize. The method is to overexpress an auxin influx carrier protein in maize, screen for transformed plants with significantly increased ear row number, grain weight per ear, or test weight, and increase the yield of maize. Overexpression of the auxin transport protein in the present invention can significantly increase the test weight and ear row number of maize kernels in inbred lines and hybrids, thereby significantly increasing the yield. Under the same genetic background, both the test weight and ear row number of kernels are positively correlated with the yield of maize. Selecting transgenic maize into which the auxin transport protein gene has been introduced using the test weight and ear row number can effectively obtain high-yield transgenic maize.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and / or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.

The present invention relates to novel oligosaccharide-carrier protein conjugates of formula (I) and their use as pharmaceuticals, particularly as vaccines. The present invention also relates to related aspects, including oligosaccharide intermediates of formulas (II) and (III) and methods for preparing such conjugates. Furthermore, the present invention relates to pharmaceutical compositions comprising the oligosaccharide-carrier protein conjugates and to the use of oligosaccharide-carrier protein conjugates of formula (IV) in biological assays. [Formula 1] JPEG2025536393000131.jpg85168

The present invention relates to an immunogenic polysaccharide-protein conjugate comprising a capsular polysaccharide (CP) from Streptococcus agalactiae (commonly known as group B streptococcus (GBS)) and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the sialic acid level of the CP is higher than about 60%. The present invention also relates to methods of making the conjugate and immunogenic compositions comprising the conjugate. The present invention also relates to an immunogenic composition comprising a polysaccharide-protein conjugate, wherein the conjugate comprises CP from GBS serotype IV and at least one additional serotype. The present invention further relates to methods of using the compositions disclosed herein to induce an immune response against GBS in a subject and / or to reduce or prevent invasive GBS disease in a subject. The antibodies generated can be used for the treatment or prevention of GBS infection by passive immunotherapy.

The application discloses a kind of areca alkaloid artificial hapten, artificial antigen and its preparation method and application, with norarecoline hydrochloride as the starting material for synthesizing artificial hapten.This areca alkaloid artificial hapten retains the characteristic structure of areca alkaloid to the greatest extent, and has active groups that can couple with carrier proteins, which can be used as antigenic determinants;Further, the areca alkaloid artificial antigen obtained can be used to immunize to obtain an anti-areca alkaloid artificial antibody with high affinity, high sensitivity and strong specificity.The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:70000, and can be used for rapid and accurate immunodetection and immunoassay of areca alkaloid.

The invention belongs to the field of biological medicine, and particularly discloses a gene editing method for improving the HDR efficiency of THP-1 cells, which comprises the following steps: selecting THP-1 cells as target cells, designing CRISPR / Cas9 gRNA for specific gene loci, preparing an alpha-donor carrier containing target gene homologous arms, and introducing the gRNA, Cas9 protein and the alpha-donor carrier into the THP-1 cells by using an electroporation transfection technology. By optimizing electroporation transfection conditions and using a novel alpha-donor carrier, the survival rate and HDR efficiency of THP-1 cells are remarkably improved. In addition, the invention also provides a kit for improving the HDR efficiency of THP-1 cells, and the kit comprises required CRISPR / Cas9 gRNA, an alpha-donor carrier, Cas9 protein, and a buffer solution and a reagent which are required by electroporation transfection. The method provides powerful support for application of gene editing in animal cell model construction, drug target screening and gene function research.

The present invention discloses a method for preparing a bivalent dysentery conjugate combination vaccine, which belongs to the technical field of biological product preparation. The vaccine includes two serotypes, 2a flexneri and sonnei. The O-specific polysaccharides of the two bacteria are covalently bound to a carrier protein according to their unique chemical structure through a corresponding chemical method to prepare a polysaccharide-protein conjugate stock solution. The polysaccharide-protein conjugate stock solution is then adsorbed with an aluminum adjuvant in an appropriate proportion to obtain a dysentery conjugate vaccine. The 2a flexneri dysentery polysaccharide is prepared as a conjugate by a reductive amine method, and the sonnei dysentery polysaccharide is prepared as a conjugate by a direct conjugation method with a spacer. In particular, the present invention no longer uses the highly toxic reagent cyanogen bromide and a high activation pH. The method is free of toxic reagents, has a mild reaction, is easy to control, and is conducive to future large-scale production. The dysentery conjugate vaccine prepared by the present invention is used for the immune prevention of infection with related serotypes of Shigella dysenteriae.

The inventive technology includes novel systems, methods, and compositions for the generation of water-soluble short-chain fatty acid phenolic compounds, preferably cannabinoids, terpenes, and other volatile compounds produced in Cannabis and other cannabinoid producing plants. In particular, the inventive technology includes novel systems and methods to solubilize short-chain fatty acid phenolic compounds, such as cannabinoids, via binding to a water soluble and readily digested carrier protein.

The present invention relates to the technical field of haptens, and particularly to a bongkrekic acid hapten, a preparation method thereof and an application. On the basis of the structure of bongkrekic acid, the present invention selects two intermediates with partial structures similar to the two ends thereof respectively for modification and coupling, adds an alanine coupling arm at a specific site, and prepares a bongkrekic acid hapten with an active amino group. After biological coupling with a carrier protein, the corresponding artificial complete antigen of bongkrekic acid can be obtained; by using the artificial complete antigen of bongkrekic acid, an antibody against bongkrekic acid can be prepared, which can be used to quickly and accurately detect bongkrekic acid in food.